CIK 0000887359 · Large accelerated filer
Vericel Corp
Sign in to watch- Ticker
- VCEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- MI
- Entity type
- operating
- EIN
- 943096597
- Phone
- 6175885555
- Business address
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Former names
- AASTROM BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,787,802
- in 7 filings, $5.8M under 10b5-1 plans
Net −$5,787,802. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Mara Joseph Anthony Jr −$4.1M Chief Financial Officer sold 82% of stake
- Flynn Sean C. −$779K Chief Legal Officer sold 88% of stake
- MCLAUGHLIN KEVIN F −$413K Director sold 28% of stake
- ZERBE ROBERT L MD −$386K Director sold 19% of stake
- SIEGAL JONATHAN −$79K Principal Accounting Officer sold 54% of stake
Reading 65 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-18 | Halpin Michael Chief Operating Officer | Option exercise | +3,825 | 13,106 | ||
| 2025-02-18 | Halpin Michael Chief Operating Officer | Shares withheld for taxes | −1,812 | $57.28 | $104K | 11,294 |
| 2025-02-18 | Halpin Michael Chief Operating Officer | Option exercise · Restricted Stock Unit | +5,250 | 10,500 | ||
| 2025-02-18 | Halpin Michael Chief Operating Officer | Option exercise · Restricted Stock Unit | +3,825 | 3,825 | ||
| 2025-02-12 | MCLAUGHLIN KEVIN F Director | Option exercise 10b5-1 | +6,000 | $3.74 | $22K | 17,900 |
| 2025-02-12 | MCLAUGHLIN KEVIN F Director | Sale 10b5-1 | −6,000 | $55.47 | $333K | 11,900 |
| 2025-02-12 | MCLAUGHLIN KEVIN F Director | Option exercise 10b5-1 | +1,000 | $2.76 | $3K | 12,900 |
| 2025-02-12 | MCLAUGHLIN KEVIN F Director | Sale 10b5-1 | −1,000 | $55.43 | $55K | 11,900 |
| 2025-02-12 | MCLAUGHLIN KEVIN F Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | +6,000 | 0 | ||
| 2025-02-12 | MCLAUGHLIN KEVIN F Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | +1,000 | 14,000 | ||
| 2025-02-07 | Rubino Alan L Director | Option exercise | +4,000 | $3.74 | $15K | 27,794 |
| 2025-02-07 | Rubino Alan L Director | Option exercise | +15,000 | $3.74 | $56K | 42,794 |
| 2025-02-07 | Rubino Alan L Director | Option exercise · Stock Option (Right to Buy) | +4,000 | 0 | ||
| 2025-02-07 | Rubino Alan L Director | Option exercise · Stock Option (Right to Buy) | +15,000 | 0 | ||
| 2025-02-05 | ZERBE ROBERT L MD Director | Option exercise 10b5-1 | +2,500 | $13.05 | $33K | 29,095 |
| 2025-02-05 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,500 | $62.50 | $156K | 26,595 |
| 2025-02-05 | ZERBE ROBERT L MD Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | +2,500 | 7,500 | ||
| 2025-02-05 | SIEGAL JONATHAN Principal Accounting Officer | Option exercise 10b5-1 | +1,092 | $48.80 | $53K | 2,298 |
| 2025-02-05 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 | −1,092 | $61.99 | $68K | 1,206 |
| 2025-02-05 | SIEGAL JONATHAN Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | +1,092 | 51,875 |
Page 20 of 75 · 1,497 trades